Opinion

Video

Future Perspectives on the Treatment Landscape for CLL

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Alberto Chiappori, MD
Matthew Cortese, MD, MPH
4 experts are featured in this series.
Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL
4 experts are featured in this series.
Related Content
Chronic Lymphocytic Leukemia | Image Credit: © LAZLO- stock.adobe.com
March 13th 2025

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Brian Czerniecki, MD
March 11th 2025

Moffitt Study Identifies Immune Response That May Stop Breast Cancer from Spreading

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Mariam F. Eskander, MD, MPH
March 10th 2025

Novel Index Identifies Social Vulnerability Barriers to Cancer Clinical Trial Enrollment

Marginal Zone Lymphoma | Image Credit: © LASZLO – stock.adobe.com
March 6th 2025

Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk, R/R CLL